Patients Treated With Multiple-Dose Oritavancin for Complicated Gram-Positive Infections
| Age/ Sex . | Infection . | Pathogen(s) . | Oritavancin Dosing . | Site(s) of Infusion . | Clinical Outcome . | Adverse Events . | Notes and Prior Therapy Outcomes . |
|---|---|---|---|---|---|---|---|
| Osteomyelitis | |||||||
| 46/M | Osteomyelitis | MSSA, S. pyogenes | 1200 mg × 6 every 6–8 d | HOIC | Cure | None | Prior amoxicillin therapy failure |
| 47/F | Osteomyelitis | MRSA | 1200 mg × 2 every 9 d | POIC | Failure | None | No prior therapy; ORI failure with change to doxycycline; eventual amputation |
| 70/F | Osteomyelitis, chronic | MRSA | 1200 mg × 10 every 7–8 d | OP-HOU | Improvement | None | No prior therapy |
| 70/M | Osteomyelitis, due to traumatic wound | S. pyogenes | 1200 mg × 2 every 6 d | HOIC | Cure | None | Prior cephalexin failure, changed to DAL with AE necessitating change to ORI |
| 55/F | Osteomyelitis | Culture-negative | 1200 mg × 3 every 14 d (with oral TMP/SMX) | POIC | Cure | None | Prior cefazolin. daptomycin, linezolid, PTZ, and VAN failures |
| 36/F | Osteomyelitis, right ankle | MSSA | 1200 mg × 2 every 14 d | POIC | Cure | None | Prior A/S, cefazolin, cephalexin, VAN, CFTX, and TMP/SMX failures |
| 58/M | Osteomyelitis, left foot | MRSA | 1200 mg × 1, then partial dose in 14 d | POIC | Improvement | Infusion-related reaction; sent to ED | Prior minocycline, VAN failure; change to linezolid following ORI AE |
| 46/F | Osteomyelitis, chronic; skull | MRSA | 1200 mg × 6 every 7–14 d | ED | Cure | None | Prior VAN therapy with improvement; patient requested hospital discharge and OPAT |
| Other Bone and Joint Infections | |||||||
| 43/F | Native septic arthritis/synovitis | Culture-negative | 1200 mg × 5 every 6–14 d | OP-HOU | Improvement | None | No prior therapy |
| 22/M | Septic arthritis/synovitis | Bacillus sp. | 1200 mg × 2 every 14 d | IP, then ED | Cure | None | Prior cefazolin failure followed by VAN improvement |
| 78/M | Prosthetic joint | Not cultured | 1200 mg × 2 every 14 d | HOIC | Cure | None | Prior TMP/SMX with improvement |
| Skin and Soft Tissue Infections: Cellulitis | |||||||
| 74/F | Cellulitis, nonpurulent | MRSA | 1200 mg × 2 every 11 d | POIC | Cure | None | Prior doxycycline with improvement |
| 86/F | Cellulitis, nonpurulent | MSSA | 1200 mg × 2 every 14 d | POIC | Improvement | None | No prior therapy |
| 75/M | Cellulitis, nonpurulent | Not cultured | 1200 mg × 2 every 14 d | POIC | Cure | None | No prior therapy |
| 60/F | Cellulitis, purulent due to surgical wound | Coagulase-negative Staphylococcus | 1200 mg × 4 every 7–17 d | OP-HOU | Improvement | None | Prior cephalexin and VAN failures; VAN therapy with AE and change to ORI |
| 67/F | Cellulitis, purulent | S. pyogenes | 1200 mg × 6 every 7–8 d | HOIC | Cure | None | Prior cefadroxil therapy failure |
| 82/M | Cellulitis, nonpurulent | Not cultured | 1200 mg × 2 every 13 d | POIC | Improvement | None | Prior PTZ and VAN therapy failure |
| 50/F | Cellulitis, nonpurulent | Not cultured | 1200 mg × 2 every 14 d | POIC | Cure | None | No prior therapy |
| 48/M | Cellulitis, nonpurulent | Not cultured | 1200 mg × 2 every 14 d | POIC | Cure | None | Prior telavancin with improvement |
| 86/F | Cellulitis, nonpurulent | MRSA | 1200 mg × 2 every 14 d | POIC | Cure | None | No prior therapy |
| 60/M | Cellulitis, nonpurulent | Not cultured | 1200 mg × 2 every 10 d | HOIC | Improvement | None | No prior therapy |
| Skin and Soft Tissue Infections: Abscess, Wound, Burn | |||||||
| 46/F | Abscess | MRSA | 1200 mg × 2 every 14 d | HOIC | Cure | None | Prior tedizolid with improvement; early relapse necessitating ORI therapy |
| 78/F | Abscess, surgical wound | MRSA | 1200 mg × 2 every 14 d | POIC | Cure | None | Prior VAN therapy with improvement |
| 60/M | Surgical wound | E. faecalis | 1200 mg × 2 every 14 d | HOIC | Improvement | None | Prior amoxicillin and TMP/SMX failure |
| 57/M | Surgical wound | Corynebacterium sp. | 1200 mg × 6 every 6–8 d | OP-HOU | Improvement | None | No prior therapy |
| 60/F | Surgical wound | Not cultured | 1200 mg × 2 every 11 d | IP, then HH | Cure | None | No prior therapy |
| 31/M | Surgical wound | MSSA | 1200 mg × 2 every 14 d | POIC | Cure | None | Prior ceftazidime, MTZ, plus VAN therapy changed to ORI for MSSA culture result |
| 67/M | Unspecified wounds | Coagulase-negative Staphylococcus | 1200 mg × 7 every 6–8 d | OP-HOU | Cure | None | Prior amoxicillin/clavulanate failure |
| 66/M | Wound, unspecified | MSSA | 1200 mg × 2 every 8 d | OP-HOU | Cure | None | Prior TMP/SMX failure |
| 56/M | Traumatic wound | Corynebacterium striatum | 1200 mg × 3 every 14 d | OP-HOU | Failure | None | No prior therapy |
| 24/M | Surgical wound, brain abscess | MRSA, MSSA | 1200 mg × 9 every 6–7 d | ED | Cure | Mild nausea | Prior CFTX, clinda, nafcillin, VAN failure |
| 51/M | Infected burn | Not cultured | 1200 mg × 2 every 7 d | HOIC | Improvement | None | Prior cefepime plus VAN therapy improvement; limb amputation still required |
| Age/ Sex . | Infection . | Pathogen(s) . | Oritavancin Dosing . | Site(s) of Infusion . | Clinical Outcome . | Adverse Events . | Notes and Prior Therapy Outcomes . |
|---|---|---|---|---|---|---|---|
| Osteomyelitis | |||||||
| 46/M | Osteomyelitis | MSSA, S. pyogenes | 1200 mg × 6 every 6–8 d | HOIC | Cure | None | Prior amoxicillin therapy failure |
| 47/F | Osteomyelitis | MRSA | 1200 mg × 2 every 9 d | POIC | Failure | None | No prior therapy; ORI failure with change to doxycycline; eventual amputation |
| 70/F | Osteomyelitis, chronic | MRSA | 1200 mg × 10 every 7–8 d | OP-HOU | Improvement | None | No prior therapy |
| 70/M | Osteomyelitis, due to traumatic wound | S. pyogenes | 1200 mg × 2 every 6 d | HOIC | Cure | None | Prior cephalexin failure, changed to DAL with AE necessitating change to ORI |
| 55/F | Osteomyelitis | Culture-negative | 1200 mg × 3 every 14 d (with oral TMP/SMX) | POIC | Cure | None | Prior cefazolin. daptomycin, linezolid, PTZ, and VAN failures |
| 36/F | Osteomyelitis, right ankle | MSSA | 1200 mg × 2 every 14 d | POIC | Cure | None | Prior A/S, cefazolin, cephalexin, VAN, CFTX, and TMP/SMX failures |
| 58/M | Osteomyelitis, left foot | MRSA | 1200 mg × 1, then partial dose in 14 d | POIC | Improvement | Infusion-related reaction; sent to ED | Prior minocycline, VAN failure; change to linezolid following ORI AE |
| 46/F | Osteomyelitis, chronic; skull | MRSA | 1200 mg × 6 every 7–14 d | ED | Cure | None | Prior VAN therapy with improvement; patient requested hospital discharge and OPAT |
| Other Bone and Joint Infections | |||||||
| 43/F | Native septic arthritis/synovitis | Culture-negative | 1200 mg × 5 every 6–14 d | OP-HOU | Improvement | None | No prior therapy |
| 22/M | Septic arthritis/synovitis | Bacillus sp. | 1200 mg × 2 every 14 d | IP, then ED | Cure | None | Prior cefazolin failure followed by VAN improvement |
| 78/M | Prosthetic joint | Not cultured | 1200 mg × 2 every 14 d | HOIC | Cure | None | Prior TMP/SMX with improvement |
| Skin and Soft Tissue Infections: Cellulitis | |||||||
| 74/F | Cellulitis, nonpurulent | MRSA | 1200 mg × 2 every 11 d | POIC | Cure | None | Prior doxycycline with improvement |
| 86/F | Cellulitis, nonpurulent | MSSA | 1200 mg × 2 every 14 d | POIC | Improvement | None | No prior therapy |
| 75/M | Cellulitis, nonpurulent | Not cultured | 1200 mg × 2 every 14 d | POIC | Cure | None | No prior therapy |
| 60/F | Cellulitis, purulent due to surgical wound | Coagulase-negative Staphylococcus | 1200 mg × 4 every 7–17 d | OP-HOU | Improvement | None | Prior cephalexin and VAN failures; VAN therapy with AE and change to ORI |
| 67/F | Cellulitis, purulent | S. pyogenes | 1200 mg × 6 every 7–8 d | HOIC | Cure | None | Prior cefadroxil therapy failure |
| 82/M | Cellulitis, nonpurulent | Not cultured | 1200 mg × 2 every 13 d | POIC | Improvement | None | Prior PTZ and VAN therapy failure |
| 50/F | Cellulitis, nonpurulent | Not cultured | 1200 mg × 2 every 14 d | POIC | Cure | None | No prior therapy |
| 48/M | Cellulitis, nonpurulent | Not cultured | 1200 mg × 2 every 14 d | POIC | Cure | None | Prior telavancin with improvement |
| 86/F | Cellulitis, nonpurulent | MRSA | 1200 mg × 2 every 14 d | POIC | Cure | None | No prior therapy |
| 60/M | Cellulitis, nonpurulent | Not cultured | 1200 mg × 2 every 10 d | HOIC | Improvement | None | No prior therapy |
| Skin and Soft Tissue Infections: Abscess, Wound, Burn | |||||||
| 46/F | Abscess | MRSA | 1200 mg × 2 every 14 d | HOIC | Cure | None | Prior tedizolid with improvement; early relapse necessitating ORI therapy |
| 78/F | Abscess, surgical wound | MRSA | 1200 mg × 2 every 14 d | POIC | Cure | None | Prior VAN therapy with improvement |
| 60/M | Surgical wound | E. faecalis | 1200 mg × 2 every 14 d | HOIC | Improvement | None | Prior amoxicillin and TMP/SMX failure |
| 57/M | Surgical wound | Corynebacterium sp. | 1200 mg × 6 every 6–8 d | OP-HOU | Improvement | None | No prior therapy |
| 60/F | Surgical wound | Not cultured | 1200 mg × 2 every 11 d | IP, then HH | Cure | None | No prior therapy |
| 31/M | Surgical wound | MSSA | 1200 mg × 2 every 14 d | POIC | Cure | None | Prior ceftazidime, MTZ, plus VAN therapy changed to ORI for MSSA culture result |
| 67/M | Unspecified wounds | Coagulase-negative Staphylococcus | 1200 mg × 7 every 6–8 d | OP-HOU | Cure | None | Prior amoxicillin/clavulanate failure |
| 66/M | Wound, unspecified | MSSA | 1200 mg × 2 every 8 d | OP-HOU | Cure | None | Prior TMP/SMX failure |
| 56/M | Traumatic wound | Corynebacterium striatum | 1200 mg × 3 every 14 d | OP-HOU | Failure | None | No prior therapy |
| 24/M | Surgical wound, brain abscess | MRSA, MSSA | 1200 mg × 9 every 6–7 d | ED | Cure | Mild nausea | Prior CFTX, clinda, nafcillin, VAN failure |
| 51/M | Infected burn | Not cultured | 1200 mg × 2 every 7 d | HOIC | Improvement | None | Prior cefepime plus VAN therapy improvement; limb amputation still required |
Abbreviations: A/S, ampicillin-sulbactam; AE, adverse event; CFTX, ceftriaxone; DAL, dalbavancin; ED, emergency department; HH, home health; HOIC, hospital-owned infusion center; IP, inpatient; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus; MTZ, metronidazole; OP-HOU, outpatient hospital observation unit; ORI, oritavancin; POIC, physician-owned infusion center; PTZ, piperacillin-tazobactam; TMP/SMX, trimethoprim-sulfamethoxazole; VAN, vancomycin.
Patients Treated With Multiple-Dose Oritavancin for Complicated Gram-Positive Infections
| Age/ Sex . | Infection . | Pathogen(s) . | Oritavancin Dosing . | Site(s) of Infusion . | Clinical Outcome . | Adverse Events . | Notes and Prior Therapy Outcomes . |
|---|---|---|---|---|---|---|---|
| Osteomyelitis | |||||||
| 46/M | Osteomyelitis | MSSA, S. pyogenes | 1200 mg × 6 every 6–8 d | HOIC | Cure | None | Prior amoxicillin therapy failure |
| 47/F | Osteomyelitis | MRSA | 1200 mg × 2 every 9 d | POIC | Failure | None | No prior therapy; ORI failure with change to doxycycline; eventual amputation |
| 70/F | Osteomyelitis, chronic | MRSA | 1200 mg × 10 every 7–8 d | OP-HOU | Improvement | None | No prior therapy |
| 70/M | Osteomyelitis, due to traumatic wound | S. pyogenes | 1200 mg × 2 every 6 d | HOIC | Cure | None | Prior cephalexin failure, changed to DAL with AE necessitating change to ORI |
| 55/F | Osteomyelitis | Culture-negative | 1200 mg × 3 every 14 d (with oral TMP/SMX) | POIC | Cure | None | Prior cefazolin. daptomycin, linezolid, PTZ, and VAN failures |
| 36/F | Osteomyelitis, right ankle | MSSA | 1200 mg × 2 every 14 d | POIC | Cure | None | Prior A/S, cefazolin, cephalexin, VAN, CFTX, and TMP/SMX failures |
| 58/M | Osteomyelitis, left foot | MRSA | 1200 mg × 1, then partial dose in 14 d | POIC | Improvement | Infusion-related reaction; sent to ED | Prior minocycline, VAN failure; change to linezolid following ORI AE |
| 46/F | Osteomyelitis, chronic; skull | MRSA | 1200 mg × 6 every 7–14 d | ED | Cure | None | Prior VAN therapy with improvement; patient requested hospital discharge and OPAT |
| Other Bone and Joint Infections | |||||||
| 43/F | Native septic arthritis/synovitis | Culture-negative | 1200 mg × 5 every 6–14 d | OP-HOU | Improvement | None | No prior therapy |
| 22/M | Septic arthritis/synovitis | Bacillus sp. | 1200 mg × 2 every 14 d | IP, then ED | Cure | None | Prior cefazolin failure followed by VAN improvement |
| 78/M | Prosthetic joint | Not cultured | 1200 mg × 2 every 14 d | HOIC | Cure | None | Prior TMP/SMX with improvement |
| Skin and Soft Tissue Infections: Cellulitis | |||||||
| 74/F | Cellulitis, nonpurulent | MRSA | 1200 mg × 2 every 11 d | POIC | Cure | None | Prior doxycycline with improvement |
| 86/F | Cellulitis, nonpurulent | MSSA | 1200 mg × 2 every 14 d | POIC | Improvement | None | No prior therapy |
| 75/M | Cellulitis, nonpurulent | Not cultured | 1200 mg × 2 every 14 d | POIC | Cure | None | No prior therapy |
| 60/F | Cellulitis, purulent due to surgical wound | Coagulase-negative Staphylococcus | 1200 mg × 4 every 7–17 d | OP-HOU | Improvement | None | Prior cephalexin and VAN failures; VAN therapy with AE and change to ORI |
| 67/F | Cellulitis, purulent | S. pyogenes | 1200 mg × 6 every 7–8 d | HOIC | Cure | None | Prior cefadroxil therapy failure |
| 82/M | Cellulitis, nonpurulent | Not cultured | 1200 mg × 2 every 13 d | POIC | Improvement | None | Prior PTZ and VAN therapy failure |
| 50/F | Cellulitis, nonpurulent | Not cultured | 1200 mg × 2 every 14 d | POIC | Cure | None | No prior therapy |
| 48/M | Cellulitis, nonpurulent | Not cultured | 1200 mg × 2 every 14 d | POIC | Cure | None | Prior telavancin with improvement |
| 86/F | Cellulitis, nonpurulent | MRSA | 1200 mg × 2 every 14 d | POIC | Cure | None | No prior therapy |
| 60/M | Cellulitis, nonpurulent | Not cultured | 1200 mg × 2 every 10 d | HOIC | Improvement | None | No prior therapy |
| Skin and Soft Tissue Infections: Abscess, Wound, Burn | |||||||
| 46/F | Abscess | MRSA | 1200 mg × 2 every 14 d | HOIC | Cure | None | Prior tedizolid with improvement; early relapse necessitating ORI therapy |
| 78/F | Abscess, surgical wound | MRSA | 1200 mg × 2 every 14 d | POIC | Cure | None | Prior VAN therapy with improvement |
| 60/M | Surgical wound | E. faecalis | 1200 mg × 2 every 14 d | HOIC | Improvement | None | Prior amoxicillin and TMP/SMX failure |
| 57/M | Surgical wound | Corynebacterium sp. | 1200 mg × 6 every 6–8 d | OP-HOU | Improvement | None | No prior therapy |
| 60/F | Surgical wound | Not cultured | 1200 mg × 2 every 11 d | IP, then HH | Cure | None | No prior therapy |
| 31/M | Surgical wound | MSSA | 1200 mg × 2 every 14 d | POIC | Cure | None | Prior ceftazidime, MTZ, plus VAN therapy changed to ORI for MSSA culture result |
| 67/M | Unspecified wounds | Coagulase-negative Staphylococcus | 1200 mg × 7 every 6–8 d | OP-HOU | Cure | None | Prior amoxicillin/clavulanate failure |
| 66/M | Wound, unspecified | MSSA | 1200 mg × 2 every 8 d | OP-HOU | Cure | None | Prior TMP/SMX failure |
| 56/M | Traumatic wound | Corynebacterium striatum | 1200 mg × 3 every 14 d | OP-HOU | Failure | None | No prior therapy |
| 24/M | Surgical wound, brain abscess | MRSA, MSSA | 1200 mg × 9 every 6–7 d | ED | Cure | Mild nausea | Prior CFTX, clinda, nafcillin, VAN failure |
| 51/M | Infected burn | Not cultured | 1200 mg × 2 every 7 d | HOIC | Improvement | None | Prior cefepime plus VAN therapy improvement; limb amputation still required |
| Age/ Sex . | Infection . | Pathogen(s) . | Oritavancin Dosing . | Site(s) of Infusion . | Clinical Outcome . | Adverse Events . | Notes and Prior Therapy Outcomes . |
|---|---|---|---|---|---|---|---|
| Osteomyelitis | |||||||
| 46/M | Osteomyelitis | MSSA, S. pyogenes | 1200 mg × 6 every 6–8 d | HOIC | Cure | None | Prior amoxicillin therapy failure |
| 47/F | Osteomyelitis | MRSA | 1200 mg × 2 every 9 d | POIC | Failure | None | No prior therapy; ORI failure with change to doxycycline; eventual amputation |
| 70/F | Osteomyelitis, chronic | MRSA | 1200 mg × 10 every 7–8 d | OP-HOU | Improvement | None | No prior therapy |
| 70/M | Osteomyelitis, due to traumatic wound | S. pyogenes | 1200 mg × 2 every 6 d | HOIC | Cure | None | Prior cephalexin failure, changed to DAL with AE necessitating change to ORI |
| 55/F | Osteomyelitis | Culture-negative | 1200 mg × 3 every 14 d (with oral TMP/SMX) | POIC | Cure | None | Prior cefazolin. daptomycin, linezolid, PTZ, and VAN failures |
| 36/F | Osteomyelitis, right ankle | MSSA | 1200 mg × 2 every 14 d | POIC | Cure | None | Prior A/S, cefazolin, cephalexin, VAN, CFTX, and TMP/SMX failures |
| 58/M | Osteomyelitis, left foot | MRSA | 1200 mg × 1, then partial dose in 14 d | POIC | Improvement | Infusion-related reaction; sent to ED | Prior minocycline, VAN failure; change to linezolid following ORI AE |
| 46/F | Osteomyelitis, chronic; skull | MRSA | 1200 mg × 6 every 7–14 d | ED | Cure | None | Prior VAN therapy with improvement; patient requested hospital discharge and OPAT |
| Other Bone and Joint Infections | |||||||
| 43/F | Native septic arthritis/synovitis | Culture-negative | 1200 mg × 5 every 6–14 d | OP-HOU | Improvement | None | No prior therapy |
| 22/M | Septic arthritis/synovitis | Bacillus sp. | 1200 mg × 2 every 14 d | IP, then ED | Cure | None | Prior cefazolin failure followed by VAN improvement |
| 78/M | Prosthetic joint | Not cultured | 1200 mg × 2 every 14 d | HOIC | Cure | None | Prior TMP/SMX with improvement |
| Skin and Soft Tissue Infections: Cellulitis | |||||||
| 74/F | Cellulitis, nonpurulent | MRSA | 1200 mg × 2 every 11 d | POIC | Cure | None | Prior doxycycline with improvement |
| 86/F | Cellulitis, nonpurulent | MSSA | 1200 mg × 2 every 14 d | POIC | Improvement | None | No prior therapy |
| 75/M | Cellulitis, nonpurulent | Not cultured | 1200 mg × 2 every 14 d | POIC | Cure | None | No prior therapy |
| 60/F | Cellulitis, purulent due to surgical wound | Coagulase-negative Staphylococcus | 1200 mg × 4 every 7–17 d | OP-HOU | Improvement | None | Prior cephalexin and VAN failures; VAN therapy with AE and change to ORI |
| 67/F | Cellulitis, purulent | S. pyogenes | 1200 mg × 6 every 7–8 d | HOIC | Cure | None | Prior cefadroxil therapy failure |
| 82/M | Cellulitis, nonpurulent | Not cultured | 1200 mg × 2 every 13 d | POIC | Improvement | None | Prior PTZ and VAN therapy failure |
| 50/F | Cellulitis, nonpurulent | Not cultured | 1200 mg × 2 every 14 d | POIC | Cure | None | No prior therapy |
| 48/M | Cellulitis, nonpurulent | Not cultured | 1200 mg × 2 every 14 d | POIC | Cure | None | Prior telavancin with improvement |
| 86/F | Cellulitis, nonpurulent | MRSA | 1200 mg × 2 every 14 d | POIC | Cure | None | No prior therapy |
| 60/M | Cellulitis, nonpurulent | Not cultured | 1200 mg × 2 every 10 d | HOIC | Improvement | None | No prior therapy |
| Skin and Soft Tissue Infections: Abscess, Wound, Burn | |||||||
| 46/F | Abscess | MRSA | 1200 mg × 2 every 14 d | HOIC | Cure | None | Prior tedizolid with improvement; early relapse necessitating ORI therapy |
| 78/F | Abscess, surgical wound | MRSA | 1200 mg × 2 every 14 d | POIC | Cure | None | Prior VAN therapy with improvement |
| 60/M | Surgical wound | E. faecalis | 1200 mg × 2 every 14 d | HOIC | Improvement | None | Prior amoxicillin and TMP/SMX failure |
| 57/M | Surgical wound | Corynebacterium sp. | 1200 mg × 6 every 6–8 d | OP-HOU | Improvement | None | No prior therapy |
| 60/F | Surgical wound | Not cultured | 1200 mg × 2 every 11 d | IP, then HH | Cure | None | No prior therapy |
| 31/M | Surgical wound | MSSA | 1200 mg × 2 every 14 d | POIC | Cure | None | Prior ceftazidime, MTZ, plus VAN therapy changed to ORI for MSSA culture result |
| 67/M | Unspecified wounds | Coagulase-negative Staphylococcus | 1200 mg × 7 every 6–8 d | OP-HOU | Cure | None | Prior amoxicillin/clavulanate failure |
| 66/M | Wound, unspecified | MSSA | 1200 mg × 2 every 8 d | OP-HOU | Cure | None | Prior TMP/SMX failure |
| 56/M | Traumatic wound | Corynebacterium striatum | 1200 mg × 3 every 14 d | OP-HOU | Failure | None | No prior therapy |
| 24/M | Surgical wound, brain abscess | MRSA, MSSA | 1200 mg × 9 every 6–7 d | ED | Cure | Mild nausea | Prior CFTX, clinda, nafcillin, VAN failure |
| 51/M | Infected burn | Not cultured | 1200 mg × 2 every 7 d | HOIC | Improvement | None | Prior cefepime plus VAN therapy improvement; limb amputation still required |
Abbreviations: A/S, ampicillin-sulbactam; AE, adverse event; CFTX, ceftriaxone; DAL, dalbavancin; ED, emergency department; HH, home health; HOIC, hospital-owned infusion center; IP, inpatient; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus; MTZ, metronidazole; OP-HOU, outpatient hospital observation unit; ORI, oritavancin; POIC, physician-owned infusion center; PTZ, piperacillin-tazobactam; TMP/SMX, trimethoprim-sulfamethoxazole; VAN, vancomycin.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
